Celgene price target raised to $186 from $171 at Cantor Cantor raised its price target on Celgene citing Revlimid test results that it believes were impressive. The firm thinks the data will support approval of Revlimid for multiple myeloma in Europe and have benefits to treatment practice in the U.S. It keeps a Buy rating on the stock.
News For CELG From The Last 14 Days
Check below for free stories on CELG the last two weeks.